Zidesamtinib is an investigational, novel brain-penetrant ROS1-selective inhibitor created with the aim to overcome limitations observed with currently available ROS1 inhibitors. Zidesamtinib is ...
NEW YORK--(BUSINESS WIRE)--AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced positive ...
The FDA approved taletrectinib (Ibtrozi)-- a next-generation oral ROS1 tyrosine kinase inhibitor (TKI) -- for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell ...
Taletrectinib, a next-generation TKI, is approved for ROS1-positive NSCLC, showing high ORR and durable responses in clinical trials. TRUST-I and TRUST-II trials demonstrated efficacy in both ...
Taletrectinib is now a preferred treatment for advanced ROS1-positive NSCLC, effective in first-line and subsequent therapies, especially for brain metastases. TRUST-I and TRUST-II trials showed high ...
Targeted cancer drugs are widely used because of their ability to inhibit specific proteins involved in cancer development with fewer side effects compared to chemotherapy drugs. But targeted ...
NEW YORK--(BUSINESS WIRE)--AnHeart Therapeutics (“AnHeart”), a clinical-stage global biopharmaceutical company committed to developing novel cancer therapies, today announced that the first patient ...
The phase 2 ARROS-1 trial will investigate NVL-520 in patients with pretreated ROS1-positive non-small cell lung cancer or other solid tumors. The phase 2 portion of the ARROS-1 clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback